Acadia pharmaceuticals announces phase 3 compass pws trial of intranasal carbetocin (acp-101) for hyperphagia in prader-willi syndrome did not meet primary endpoint

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced top-line results from the phase 3 compass pws trial evaluating the efficacy and safety of intranasal carbetocin (acp-101) in patients with hyperphagia in prader-willi syndrome (pws). intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, change from baseline to week 12 on the hyperphagia questionnaire for clinical trials (hq-ct), nor was.
ACAD Ratings Summary
ACAD Quant Ranking